Skip to main content

Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results

Breast Cancer volume 26, pages 106–112 (2019)Cite this article

Abstract

Background

Aromatase inhibitors (AI) have been established as the gold-standard therapy for postmenopausal patients. Worldwide, adjuvant denosumab at a dose of 60 mg twice per year reduces the risk of clinical fractures in postmenopausal patients with breast cancer who received AI. However, the efficacy of denosumab in the treatment of AI-associated bone loss had not been prospectively evaluated in Japan. Previously, we reported the 12-month effect of denosumab in Japanese patients for the first time; the primary endpoint was the change in the percentage of bone mineral density (BMD) of the lumbar spine from baseline to 12 months.

Methods

This secondary follow-up study prospectively evaluated the change in the percentage of BMD of the lumbar spine from baseline to 24 months. Postmenopausal women with early-stage, histologically confirmed, hormone receptor-positive, invasive breast cancer who were receiving or scheduled to receive AI were included. Denosumab was administered subcutaneously on day 1 of the study and then 6, 12, 18, and 24 months. The lumbar spine and bilateral femoral neck BMD was measured at baseline and 6, 12, 18, and 24 months.

Results

At 18 and 24 months, the lumbar spine BMD increased by 5.9 and 7.0%, respectively. The femoral neck BMD also increased. Grade ≥ 2 hypocalcemia, osteonecrosis of the jaw, and atypical femoral fractures did not occur.

Conclusions

Our prospective study showed that semiannual treatment with denosumab was associated with continuously increased BMD in Japanese women receiving adjuvant AI therapy for up to 24 months, regardless of prior AI treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Wang J, Lv H, Xue Z, Wang L, Bai Z, et al. Temporal trends of common female malignances on breast, cervical, and ovarian cancer mortality in Japan, Republic of Korea, and Singapore: application of the age-period-cohort model. Biomed Res Int. 2018;5307459:13

    Google Scholar 

  2. Gradishar W, Salerno KE. NCCN guidelines update: breast cancer. J Natl Compr Canc Netw. 2016;14:641–4.

    Article  CAS  PubMed  Google Scholar 

  3. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009;69:73–82.

    Article  PubMed  Google Scholar 

  4. Lee SJ, Kim KM, Brown JK, Brett A, Roh YH, Kang DR, et al. Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer. Calcif Tissue Int. 2015;97:551–9.

    Article  CAS  PubMed  Google Scholar 

  5. Kim W, Chung Y, Kim SH, Park S, Bae JH, Kim G, et al. Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab (Seoul). 2015;30:58–64.

    Article  CAS  Google Scholar 

  6. Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, et al. Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol. 2009;20:1203–9.

    Article  CAS  PubMed  Google Scholar 

  7. Kyvernitakis I, Rachner TD, Urbschat A, Hars O, Hofbauer LC, Hadji P. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J Cancer Res Clin Oncol. 2014;140:1671–80.

    Article  CAS  PubMed  Google Scholar 

  8. Kyvernitakis I, Knoll D, Struck M, Hars O, Bauer T, Hadji P. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. J Cancer Res Clin Oncol. 2014;140:159–66.

    Article  CAS  PubMed  Google Scholar 

  9. Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet. 2015;366:431–33.

    Article  Google Scholar 

  10. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119–27.

    Article  CAS  PubMed  Google Scholar 

  11. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71.

    Article  CAS  PubMed  Google Scholar 

  12. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 2007;25:486–92.

    Article  CAS  PubMed  Google Scholar 

  13. Nakatsukasa K, Koyama J, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, et al. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab. 2018. https://doi.org/10.1007/s00774-018-0917-0.

    Article  PubMed  Google Scholar 

  14. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesez R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet. 2015;386:433–43.

    Article  CAS  PubMed  Google Scholar 

  15. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US preventive services task force recommendations. Ann Intern Med. 2012;157:104–13.

    Article  PubMed  Google Scholar 

  16. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056–61.

    Article  CAS  PubMed  Google Scholar 

  17. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone. 2002;30:18–25.

    Article  CAS  PubMed  Google Scholar 

  18. Callewaert F, Venken K, Ophoff J, De Gendt K, Torcasio A, van Lenthe GH, et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J. 2009;23:232–40.

    Article  CAS  PubMed  Google Scholar 

  19. Ford J, Hajibeigi A, Long M, Hahner L, Gore C, Hsieh JT, et al. GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. J Bone Miner Res. 2011;26:298–307.

    Article  CAS  PubMed  Google Scholar 

  20. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145:527–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.

    Article  CAS  PubMed  Google Scholar 

  22. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95:3597–602.

    Article  CAS  PubMed  Google Scholar 

  23. Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173–79.

    Article  CAS  PubMed  Google Scholar 

  24. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2012;27:243–54.

    Article  CAS  PubMed  Google Scholar 

  25. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–23.

    Article  CAS  PubMed  Google Scholar 

  26. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–48.

    Article  CAS  Google Scholar 

  27. Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25:2256–65.

    Article  CAS  PubMed  Google Scholar 

  28. Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen LE, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res. 2014;29:2051–56.

    Article  CAS  PubMed  Google Scholar 

  29. Montagner F, Kaftandjian V, Farlay D, Brau D, Boivin G, Follet H. Validation of a novel microradiography device for characterization of bone mineralization. J X-ray Sci Technol. 2015;23:201–11.

    CAS  Google Scholar 

  30. Vittinghoff E, McCulloch CE, Woo C, Cummings SR. Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med. 2010;29:1127–36.

    PubMed  Google Scholar 

  31. Ota S, Inoue R, Shiozaki T, Yamamoto Y, Hashimoto N, Takeda O, et al. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. Breast Cancer. 2017;24:601–7.

    Article  PubMed  Google Scholar 

  32. Shabestari M, Eriksenb EF, Paschalis EP, Roschger P, Gamsjaeger S, Klaushofer K, et al. Presence of pyrophosphate in bone from an atypical femoral fracture site: a case report. Bone Rep. 2017;6:81–6.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Japanese Allied Committee on Osteonecrosis of the Jaw. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, et al. Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017;35:6–19.

    Article  CAS  Google Scholar 

  34. Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016;27:1917–21.

    Article  CAS  PubMed  Google Scholar 

  35. Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102:354–8.

    Article  PubMed  Google Scholar 

  36. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res. 2018;33:190–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Grants-in-Aid for Scientific Research from the Japanese Breast Cancer Society.

Author information

Affiliations

  1. Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan

    Katsuhiko Nakatsukasa, Yoshimi Ouchi, Hisako Ono, Kouichi Sakaguchi & Tetsuya Taguchi

  2. Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Hisako Ono

  3. Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Eiichi Konishi

  4. Nara City Hospital, Nara, Japan

    Hiroshi Koyama

  5. Saiseikai Kyoto Hospital, Kyoto, Japan

    Takayuki Matsuda

  6. Kato Breast Surgery Clinic, Kyoto, Japan

    Makoto Kato

  7. Department of Breast, Tokyo Medical University, Tokyo, Japan

    Takashi Ishikawa & Kimito Yamada

  8. Department of Radiology, Tokyo Medical University, Tokyo, Japan

    Mana Yoshimura

  9. Department of Breast Oncology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

    Kei Koizumi

  10. Department of Surgery, Wakayama Medical University Kihoku Hospital, Wakayama, Japan

    Teruhisa Sakurai

  11. Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure-City, Hiroshima, Japan

    Hideo Shigematsu

  12. Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

    Shunji Takahashi & Shinichiro Taira

  13. Department of Breast Surgery, National Hospital Organization Chiba Medical Center, Yokohama City University Medical Center, Tokyo, Japan

    Masato Suzuki

  14. Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, 232-0024, Japan

    Kazutaka Narui

  15. Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Tokyo, Japan

    Naoki Niikura

  16. Department of Breast Surgical Oncology, Hirosaki Municipal Hospital, Hirosaki, Japan

    Yoshie Hasegawa

  17. Akasaka Miura Clinic, Tokyo, Japan

    Daishu Miura

Authors
  1. Katsuhiko Nakatsukasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshimi Ouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisako Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kouichi Sakaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takayuki Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Makoto Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takashi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kimito Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mana Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kei Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Teruhisa Sakurai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hideo Shigematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shunji Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shinichiro Taira
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Masato Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Kazutaka Narui
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Naoki Niikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Yoshie Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Daishu Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Eiichi Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Tetsuya Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Corresponding author

Correspondence to Tetsuya Taguchi.

Ethics declarations

Conflict of interest

Dr Tetsuya Taguchi received Research grant from Chugai, Taiho and Daiichi Sankyo. Dr Shunji Takahashi received Research grant from Daiichi Sankyo. Other authors declare that they have no conflict of interest.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standard.

Informed consent

Informed consent was obtained from all individual participants included in the study.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nakatsukasa, K., Koyama, H., Ouchi, Y. et al. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. Breast Cancer 26, 106–112 (2019). https://doi.org/10.1007/s12282-018-0896-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-018-0896-y

Keywords

  • Breast cancer
  • Aromatase inhibitor
  • Denosumab
  • Bone mineral density